Table 1 General data of AAV patients

 Sex (Male/Female)

31/49

51/77

0.88

 Age (years)

57.2 ± 12.3

59.4 ± 14.5

0.27

 Hypertension (n %)

20/25.0

45/35.2

0.12

 Cardiovascular disease (n %)

11/13.8

19/14.8

0.83

 Diabetes (n %)

10/12.5

26/20.3

0.15

 Using ACEI/ARB (n %)

18/22.5

22/17.2

0.34

 ANCA subtypes (PR3/MPO)

11/69

13/115

0.43

 ANCA level (RU/mL)

187.0 (96.0,200.0)

143.5(88.8,200.0)

0.37

 BVAS

19.1 ± 6.9

18.4 ± 6.8

0.58

 Hemoglobin (g/L)

97.5 ± 21.2

101.4 ± 20.5

0.22

 Leukocyte (×10⁹/L)

8.5 ± 2.9

9.7 ± 3.2

0.011

 Neutrophil (×10⁹/L)

6.4 ± 2.9

7.4 ± 3.1

0.04

 Platelets (×10⁹/L)

259.4 ± 102.3

267.9 ± 98.3

0.59

 ESR (mm/1 h)

56.5(43.5,79.8)

80.0(35.0,104.0)

0.09

 C-reactive protein (mg/L)

9.8(3.5,39.2)

16.3(7.2,64.2)

0.11

 Urine protein excretion (g/24 h)

1.0(0.3,1.8)

0.9(0.6,2.1)

0.56

 Serum creatinine (μmol/L)

167.5(111.5,341. 0)

154.5(95.1,312.0)

0.50

 eGFR (mL/min/1.73 m2)^a

39.2 ± 28.9

42.9 ± 31.1

0.39

 Fever (n/%)

31/38.8

60/46.9

0.25

 Fatigue (n/%)

36/45.0

74/57.8

0.07

 Rash (n/%)

10/12.5

20/15.6

0.53

 Weight loss (n/%)

31/38.8

69/53.9

0.033

 Muscle pain (n/%)

13/16.3

31/24.2

0.17

 Arthralgia (n/%)

15/18.8

25/19.5

0.89

 Lung (n/%)

49/61.3

74/57.8

0.62

 ENT (n/%)

37/46.3

59/46.1

0.98

 Gastrointestinal tract (n/%)

23/28.8

39/30.5

0.79

 Nervous system (n/%)

7/8.8

24/18.8

0.049

 Prednisone-equivalent dose (g)

8.9 ± 4.0

9.2 ± 3.1

0.53

 Oral CTX/IV CTX

8/72

19/109

0.07

 Serum creatinine (μmol/L)

115.5(96.5,145.0)

114.0(90.0,154.8)

0.68

 eGFR (mL/min/1.73m²)

54.1 ± 21.2

55.8 ± 24.7

0.61

 ANCA level (RU/mL)

42.5(0.0,81.8)

0.0(0.0,51.0)

0.017

 ESR (mm/1 h)

20.0(11.0,33.0)

19.0(14.0,33.0)

0.65

 C-reactive protein (mg/L)

3.0(1.0,8.0)

3.0(1.0,8.0)

0.86

 Proteinuria (n/%)^b

48(61.5%)

52(40.6%)

0.004

 IV CTX every 3 mo/AZA/MMF

25/53/2

34/86/8

0.61

 The slope of eGFR decline (mL/min/1.73 m²/y)

3.6(1.2,7.2)

1.5(0.2,4.0)

<0.001